Dataset Information

Primary antibody response after influenza virus infection is first dominated by low-mutated HA-stem antibodies followed by higher-mutated HA-head antibodies.

ABSTRACT: Several studies have shown that the first encounter with influenza virus shapes the immune response to future infections or vaccinations. However, a detailed analysis of the primary antibody response is lacking as this is difficult to study in humans. It is therefore not known what the frequency and dynamics of the strain-specific hemagglutinin (HA) head- and stem-directed antibody responses are directly after primary influenza virus infection. Here, sera of twelve H1N1_pdm2009 influenza virus-infected cynomolgus macaques were evaluated for HA-head and HA-stem domain antibody responses. We observed an early induction of HA-stem antibody responses, which was already decreased by day 56. In contrast, responses against the HA-head domain were low early after infection and increased at later timepoint. The HA-specific B cell repertoires in each animal showed diverse VH-gene usage with preferred VH-gene and JH-gene family usage for HA-head or HA-stem B cells but a highly diverse allelic variation within the VH-usage. HA-head B cells had shorter CDRH3s and higher VH-gene somatic hyper mutation levels relative to HA-stem B cells. In conclusion, our data suggest that HA-stem antibodies are the first to react to the infection while HA-head antibodies show a delayed response, but a greater propensity to enter the germinal center and undergo affinity maturation.

SUBMITTER: Aartse A

PROVIDER: S-EPMC9670313 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Primary antibody response after influenza virus infection is first dominated by low-mutated HA-stem antibodies followed by higher-mutated HA-head antibodies.

Aartse Aafke A Mortier Daniella D Mooij Petra P Hofman Sam S van Haaren Marlies M MM Corcoran Martin M Karlsson Hedestam Gunilla B GB Eggink Dirk D Claireaux Mathieu M Bogers Willy M J M WMJM van Gils Marit J MJ Koopman Gerrit G

Frontiers in immunology 20221103

Several studies have shown that the first encounter with influenza virus shapes the immune response to future infections or vaccinations. However, a detailed analysis of the primary antibody response is lacking as this is difficult to study in humans. It is therefore not known what the frequency and dynamics of the strain-specific hemagglutinin (HA) head- and stem-directed antibody responses are directly after primary influenza virus infection. Here, sera of twelve H1N1<sub>pdm2009</sub> influen ...[more]

PMID: 36405682

Similar Datasets

Project description:In this study, we examined the relationships between anti-influenza virus serum antibody titers, clinical disease, and peripheral blood leukocyte (PBL) global gene expression during presymptomatic, acute, and convalescent illness in 83 participants infected with 2009 pandemic H1N1 virus in a human influenza challenge model. Using traditional statistical and logistic regression modeling approaches, profiles of differentially expressed genes that correlated with active viral shedding, predicted length of viral shedding, and predicted illness severity were identified. These analyses further demonstrated that challenge participants fell into three peripheral blood leukocyte gene expression phenotypes that significantly correlated with different clinical outcomes and prechallenge serum titers of antibodies specific for the viral neuraminidase, hemagglutinin head, and hemagglutinin stalk. Higher prechallenge serum antibody titers were inversely correlated with leukocyte responsiveness in participants with active disease and could mask expression of peripheral blood markers of clinical disease in some participants, including viral shedding and symptom severity. Consequently, preexisting anti-influenza antibodies may modulate PBL gene expression, and this must be taken into consideration in the development and interpretation of peripheral blood diagnostic and prognostic assays of influenza infection.IMPORTANCE Influenza A viruses are significant human pathogens that caused 83,000 deaths in the United States during 2017 to 2018, and there is need to understand the molecular correlates of illness and to identify prognostic markers of viral infection, symptom severity, and disease course. Preexisting antibodies against viral neuraminidase (NA) and hemagglutinin (HA) proteins play a critical role in lessening disease severity. We performed global gene expression profiling of peripheral blood leukocytes collected during acute and convalescent phases from a large cohort of people infected with A/H1N1pdm virus. Using statistical and machine-learning approaches, populations of genes were identified early in infection that correlated with active viral shedding, predicted length of shedding, or disease severity. Finally, these gene expression responses were differentially affected by increased levels of preexisting influenza antibodies, which could mask detection of these markers of contagiousness and disease severity in people with active clinical disease.

Project description:Molecular Features of the Serological IgG Repertoire Elicited by Egg-based, Cell-based, or Recombinant HA Seasonal Influenza Vaccines. __sample information__ Donorname day0S1 or day28S2 Elu or FT Pf number A1 S1 FT 7649_JL_5a.raw A1 S1 FT 7649_JL_5b.raw A1 S1 FT 7649_JL_5c.raw A1 S2 FT 7649_JL_7a.raw A1 S2 FT 7649_JL_7b.raw A1 S2 FT 7649_JL_7c.raw A1 S1 Elu 7649_JL_6a.raw A1 S1 Elu 7649_JL_6b.raw A1 S1 Elu 7649_JL_6c.raw A1 S2 Elu 7649_JL_8a.raw A1 S2 Elu 7649_JL_8b.raw A1 S2 Elu 7649_JL_8c.raw A2 S1 FT 8078_JP_1a.raw A2 S1 FT 8078_JP_1b.raw A2 S1 FT 8078_JP_1c.raw A2 S2 FT 8078_JP_2a.raw A2 S2 FT 8078_JP_2b.raw A2 S2 FT 8078_JP_2c.raw A2 S1 Elu 8078_JP_3a.raw A2 S1 Elu 8078_JP_3b.raw A2 S1 Elu 8078_JP_3c.raw A2 S2 Elu 8078_JP_4a.raw A2 S2 Elu 8078_JP_4b.raw A2 S2 Elu 8078_JP_4c.raw A3 S1 FT 8116_JP_1a.raw A3 S1 FT 8116_JP_1b.raw A3 S1 FT 8116_JP_1c.raw A3 S2 FT 8116_JP_2a.raw A3 S2 FT 8116_JP_2b.raw A3 S2 FT 8116_JP_2c.raw A3 S1 Elu 8116_JP_3a.raw A3 S1 Elu 8116_JP_3b.raw A3 S1 Elu 8116_JP_3c.raw A3 S2 Elu 8116_JP_4a.raw A3 S2 Elu 8116_JP_4b.raw A3 S2 Elu 8116_JP_4c.raw A4 S1 FT 8149_JP_1a.raw A4 S1 FT 8149_JP_1b.raw A4 S1 FT 8149_JP_1c.raw A4 S2 FT 8149_JP_2a.raw A4 S2 FT 8149_JP_2b.raw A4 S2 FT 8149_JP_2c.raw A4 S1 Elu 8149_JP_3a.raw A4 S1 Elu 8149_JP_3b.raw A4 S1 Elu 8149_JP_3c.raw A4 S2 Elu 8149_JP_4a.raw A4 S2 Elu 8149_JP_4b.raw A4 S2 Elu 8149_JP_4c.raw A5 S1 FT 8209_JP_1a.raw A5 S1 FT 8209_JP_1b.raw A5 S1 FT 8209_JP_1c.raw A5 S2 FT 8209_JP_2a.raw A5 S2 FT 8209_JP_2b.raw A5 S2 FT 8209_JP_2c.raw A5 S1 Elu 8209_JP_3a.raw A5 S1 Elu 8209_JP_3b.raw A5 S1 Elu 8209_JP_3c.raw A5 S2 Elu 8209_JP_4a.raw A5 S2 Elu 8209_JP_4b.raw A5 S2 Elu 8209_JP_4c.raw B1 S1 FT 7924_JL_1a.raw B1 S1 FT 7924_JL_1b.raw B1 S1 FT 7924_JL_1c.raw B1 S2 FT 7924_JL_2a.raw B1 S2 FT 7924_JL_2b.raw B1 S2 FT 7924_JL_2c.raw B1 S1 Elu 7924_JL_4a.raw B1 S1 Elu 7924_JL_4b.raw B1 S1 Elu 7924_JL_4c.raw B1 S2 Elu 7924_JL_5a.raw B1 S2 Elu 7924_JL_5b.raw B1 S2 Elu 7924_JL_5c.raw B2 S1 FT 7947_JL_1a.raw B2 S1 FT 7947_JL_1b.raw B2 S1 FT 7947_JL_1c.raw B2 S2 FT 7947_JL_2a.raw B2 S2 FT 7947_JL_2b.raw B2 S2 FT 7947_JL_2c.raw B2 S1 Elu 7947_JL_3a.raw B2 S1 Elu 7947_JL_3b.raw B2 S1 Elu 7947_JL_3c.raw B2 S2 Elu 7947_JL_4a.raw B2 S2 Elu 7947_JL_4b.raw B2 S2 Elu 7947_JL_4c.raw B3 S1 FT 8129_JL_1a.raw B3 S1 FT 8129_JL_1b.raw B3 S1 FT 8129_JL_1c.raw B3 S2 FT 8129_JL_2a.raw B3 S2 FT 8129_JL_2b.raw B3 S2 FT 8129_JL_2c.raw B3 S1 Elu 8129_JL_3a.raw B3 S1 Elu 8129_JL_3b.raw B3 S1 Elu 8129_JL_3c.raw B3 S2 Elu 8129_JL_4a.raw B3 S2 Elu 8129_JL_4b.raw B3 S2 Elu 8129_JL_4c.raw B4 S1 FT 8164_JP_1a.raw B4 S1 FT 8164_JP_1b.raw B4 S1 FT 8164_JP_1c.raw B4 S2 FT 8164_JP_2a.raw B4 S2 FT 8164_JP_2b.raw B4 S2 FT 8164_JP_2c.raw B4 S1 Elu 8164_JP_3a.raw B4 S1 Elu 8164_JP_3b.raw B4 S1 Elu 8164_JP_3c.raw B4 S2 Elu 8164_JP_4a.raw B4 S2 Elu 8164_JP_4b.raw B4 S2 Elu 8164_JP_4c.raw B5 S1 FT 8237_JP_1a.raw B5 S1 FT 8237_JP_1b.raw B5 S1 FT 8237_JP_1c.raw B5 S2 FT 8237_JP_2a.raw B5 S2 FT 8237_JP_2b.raw B5 S2 FT 8237_JP_2c.raw B5 S1 Elu 8237_JP_3a.raw B5 S1 Elu 8237_JP_3b.raw B5 S1 Elu 8237_JP_3c.raw B5 S2 Elu 8237_JP_4a.raw B5 S2 Elu 8237_JP_4b.raw B5 S2 Elu 8237_JP_4c.raw C1 S1 FT 8108_JP_1a.raw C1 S1 FT 8108_JP_1b.raw C1 S1 FT 8108_JP_1c.raw C1 S2 FT 8108_JP_2a.raw C1 S2 FT 8108_JP_2b.raw C1 S2 FT 8108_JP_2c.raw C1 S1 Elu 8108_JP_3a.raw C1 S1 Elu 8108_JP_3b.raw C1 S1 Elu 8108_JP_3c.raw C1 S2 Elu 8108_JP_4a.raw C1 S2 Elu 8108_JP_4b.raw C1 S2 Elu 8108_JP_4c.raw C2 S1 FT 8048_JL_1a.raw C2 S1 FT 8048_JL_1b.raw C2 S1 FT 8048_JL_1c.raw C2 S2 FT 8048_JL_2a.raw C2 S2 FT 8048_JL_2b.raw C2 S2 FT 8048_JL_2c.raw C2 S1 Elu 8048_JL_3a.raw C2 S1 Elu 8048_JL_3b.raw C2 S1 Elu 8048_JL_3c.raw C2 S2 Elu 8048_JL_4a.raw C2 S2 Elu 8048_JL_4b.raw C2 S2 Elu 8048_JL_4c.raw C3 S1 FT 8068_JP_1a.raw C3 S1 FT 8068_JP_1b.raw C3 S1 FT 8068_JP_1c.raw C3 S2 FT 8068_JP_2a.raw C3 S2 FT 8068_JP_2b.raw C3 S2 FT 8068_JP_2c.raw C3 S1 Elu 8068_JP_3a.raw C3 S1 Elu 8068_JP_3b.raw C3 S1 Elu 8068_JP_3c.raw C3 S2 Elu 8108_JP_5a.raw C3 S2 Elu 8108_JP_5b.raw C3 S2 Elu 8108_JP_5c.raw C4 S1 FT 8203_JP_1a.raw C4 S1 FT 8203_JP_1b.raw C4 S1 FT 8203_JP_1c.raw C4 S2 FT 8203_JP_2a.raw C4 S2 FT 8203_JP_2b.raw C4 S2 FT 8203_JP_2c.raw C4 S1 Elu 8203_JP_3a.raw C4 S1 Elu 8203_JP_3b.raw C4 S1 Elu 8203_JP_3c.raw C4 S2 Elu 8203_JP_4a.raw C4 S2 Elu 8203_JP_4b.raw C4 S2 Elu 8203_JP_4c.raw C5 S1 FT 8258_JP_1a.raw C5 S1 FT 8258_JP_1b.raw C5 S1 FT 8258_JP_1c.raw C5 S2 FT 8258_JP_2a.raw C5 S2 FT 8258_JP_2b.raw C5 S2 FT 8258_JP_2c.raw C5 S1 Elu 8258_JP_3a.raw C5 S1 Elu 8258_JP_3b.raw C5 S1 Elu 8258_JP_3c.raw C5 S2 Elu 8258_JP_4a.raw C5 S2 Elu 8258_JP_4b.raw C5 S2 Elu 8258_JP_4c.raw

Project description:The H7N9 subtype influenza A viruses pose a serious threat to public health, and there is still a lack of vaccines or drugs for humans against H7N9 influenza viruses. In this study, we screened two monoclonal antibodies (MAbs), 4H1E8 and 7H9A6, that specifically recognize the hemagglutinin (HA) protein of H7N9 influenza virus and display highly neutralizing activity against H7N9 virus. The epitopes recognized by two MAbs are nearly all conserved within all known H7 subtypes. Characteristic identification showed that two MAbs have high avidity for the HA protein but no hemagglutinin inhibition activity or antibody-dependent cellular cytotoxicity. Mechanistically, the 4H1E8 and 7H9A6 antibodies inhibit the pH-dependent conformational change of HA and block the HA-mediated membrane fusion. More importantly, 4H1E8 and 7H9A6 exhibit promising prophylactic and therapeutic effects against lethal challenge with H7N9 virus. Moreover, 4H1E8- and 7H9A6-treated mice displayed inhibition of pulmonary viral replication and reduced lung lesions after viral challenge. Together, these findings indicate that antibodies 4H1E8 and 7H9A6 recognize unique epitopes in the HA protein and possess the neutralizing activity and protective efficacy against the H7N9 influenza A viruses. IMPORTANCE In 2013, H7N9 influenza viruses appeared in China and other countries resulting in more than 1,500 individual infections or death. There are still limited studies on vaccines or drugs for humans against H7N9 influenza viruses. Alternative approaches against H7N9 virus infection need to be developed. Here, we identified two monoclonal antibodies (4H1E8 and 7H9A6) that possess neutralizing activity by blocking the pH-dependent HA-mediated membrane fusion. Additionally, the two monoclonal antibodies protect mice against the H7N9 virus challenge prophylactically or therapeutically. Therefore, our study demonstrates that 4H1E8 and 7H9A6 could be used for the prevention and treatment of the H7N9 influenza virus, and the conserved epitopes we identified may contribute to the development of a broad H7N9 vaccine and provide insights into unique antiviral approaches.

Dataset Information

Primary antibody response after influenza virus infection is first dominated by low-mutated HA-stem antibodies followed by higher-mutated HA-head antibodies.

Publications

Primary antibody response after influenza virus infection is first dominated by low-mutated HA-stem antibodies followed by higher-mutated HA-head antibodies.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets